Sublingual Apomorphine in Refractory Restless Legs Syndrome
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS)
patients inadequately treated with standard therapy. Investigators hypothesize that the study
drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is
designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS
patients, in addition to subjective responses.